文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症消化、代谢与肾脏急症

留尼汪岛重症监护病房成人重症登革热:临床谱、结局与死亡预测因素

Severe dengue in adults admitted to intensive care units on réunion island: clinical spectrum, outcomes, and predictors of mortality.
PubMed 文献 · Crit Care · 2025-11-27
一句话结论留尼汪岛5个ICU 137例成人重症登革热住院病死率25%,休克和器官衰竭而非出血是主要死因,儿茶酚胺使用和入院呼吸频率是独立死亡预测因素。

该多中心回顾性研究纳入2017年1月至2022年12月留尼汪岛5个ICU收治的137例实验室确诊成人重症登革热(CDC标准)。循环衰竭占62%(分布性休克12%、心肌炎9%),肝衰竭50%、肾衰竭59%、神经表现9%,合并感染33%,38%入院时初诊非登革热。住院病死率25%,儿茶酚胺使用(OR 4.71,95%CI 1.58–14.07,p=0.005)和入院呼吸频率(OR 1.10,95%CI 1.03–1.17,p=0.004)为独立死亡预测因素。死亡主要归因于多器官衰竭而非出血并发症。

要点

  • 重症登革热ICU患者住院病死率25%,死亡主要归因于多器官衰竭而非出血并发症。
  • 循环衰竭见于62%患者,其中分布性休克12%、心肌炎9%,6例需VA-ECMO。
  • 儿茶酚胺使用是独立死亡预测因素(OR 4.71,95%CI 1.58–14.07,p=0.005)。
  • 入院呼吸频率是独立死亡预测因素(OR 1.10,95%CI 1.03–1.17,p=0.004)。
  • 合并感染占33%,38%入院时初诊非登革热,肝衰竭50%、肾衰竭59%。

适用人群与场景

  • 2017年1月至2022年12月留尼汪岛5个ICU收治的成人(中位年龄63岁,IQR 50–70;男性62%)实验室确诊重症登革热患者,诊断采用美国疾病控制与预防中心(CDC)标准。

诊断标准与关键阈值

  • 重症登革热诊断采用美国疾病控制与预防中心(CDC)标准。

红旗征与不能漏的情况

  • 循环衰竭(62%)、分布性休克(12%)、心肌炎(9%)、肝衰竭(50%)、肾衰竭(59%)、神经表现(9%)为重症表现,需收入ICU处理。
  • 6例患者需静脉-动脉体外膜氧合(VA-ECMO)支持。

研究设计与关键结果

  • 多中心回顾性研究:72,434例确诊病例中2,817例需住院,137例重症登革热收入ICU(1.8/1000感染);中位年龄63岁(IQR 50–70),男性62%。
  • 循环衰竭62%(分布性休克12%、心肌炎9%),6例需VA-ECMO;肝衰竭50%、肾衰竭59%、神经表现9%(13例);合并感染33%;52例(38%)入院初诊非登革热;血小板减少78%,出血事件不常见。
  • 住院病死率25%;儿茶酚胺使用(OR 4.71,95%CI 1.58–14.07,p=0.005)和入院呼吸频率(OR 1.10,95%CI 1.03–1.17,p=0.004)为独立死亡预测因素。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,早期识别和优化管理休克与器官功能障碍仍是改善未来登革热暴发期间生存的关键。
  • 重症登革热ICU患者中合并感染常见(33%),38%入院时初诊非登革热,作者认为合并症可能促成了不良结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Since 2017, Réunion Island has experienced successive dengue epidemics involving the co-circulation of DENV-1 and DENV-2 serotypes, leading to an increased number of severe cases. This study aimed to describe the clinical characteristics outcomes, and predictors of in-hospital mortality among adults admitted to intensive care units (ICUs) for severe dengue. METHODS: We conducted a multicenter retrospective study including all adults admitted to the five ICUs of Réunion Island between January 2017 and December 2022 with laboratory-confirmed severe dengue (SD), as defined by U.S. Centers for Disease Control and Prevention criteria. Clinical, biological, and outcome data were collected from electronic records. Significant variables in univariate analysis (p < 0.05) were entered into a multivariate logistic regression model to identify independent predictors of mortality. RESULTS: Among 72.434 confirmed dengue cases, 2.817 required hospitalization and 137 SD were admitted to ICUs (1.8 per 1,000 infections). The median age was 63 years (IQR 50–70), and 62% were male. Circulatory failure occurred in 62% of cases including 12% with distributive shock and 9% with myocarditis; six patients required veno-arterial extra corporeal membrane oxygenation (VA-ECMO). Hepatic and renal failures were respectively observed in 50% and 59% of patients and neurological presentations occurred in 13 patients (9%). Co-infection were present in 33% of cases and fifty-two patients (38%) were admitted with an initial diagnosis other than dengue. Despite thrombocytopenia in 78% of cases, hemorrhagic events were uncommon. The in-hospital mortality rate was 25%. Catecholamine use (OR 4.71 [1.58–14.07], p = 0.005) and respiratory rate at admission (OR 1.10 [1.03–1.17], p = 0.004) were independent predictors of mortality. CONCLUSIONS: SD on Réunion Island exhibited a wide clinical spectrum in ICUs and was associated with substantial mortality, primarily due to multiple organ failure rather than hemorrhagic complications. Co-infections were common, and comorbidities likely contributed to unfavorable outcomes. Early identification and optimal management of shock and organ dysfunction remain essential to improving survival during future dengue outbreaks.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Vidal C, Soupin-Coulin Q, Doucet W, et al. Severe dengue in adults admitted to intensive care units on réunion island: clinical spectrum, outcomes, and predictors of mortality. Crit Care. 2025. PMID: 41310777. doi:10.1186/s13054-025-05779-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。